Session Information

WCLC 2017

18th World Conference on Lung Cancer

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan

Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.
Presentation Date(s):
- Oct 15 - 18, 2017
- Total Presentations: 2295
Register to Attend WCLC Return to WCLC 2017 Website Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18

Filter Results:

Show Only CME Accredited Sessions

18982

+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
- 22317
  
  +
  
  JCSE 01.25 - Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC
  
  11:30 - 11:30 | Presenter: Xu-Chao Zhang | Author(s): Z. Liang, Y. Chen, H. Zhang, W. Gang, Y. Lu, Z. Liang, Ying Cheng, Y. Hu, Jie Wang, J. Ying, W. Liu, Yi-Long Wu
  Abstract
  
  Loading...
20203

+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 22440
  
  +
  
  P1.01-034 - Cerebrospinal Fluid and Plasma Tumor DNA Profiling Reveals Heterogeneity of CNS Metastasis in Patients with Non-Small-Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Panwen Tian | Author(s): Y. Wang, D. Liu, X. Du, L. Li, W. Li
  Abstract
  
  Loading...
18971

+
P1.02 - Biology/Pathology
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- 22530
  
  +
  
  P1.02-046 - Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations
  
  09:30 - 09:30 | Presenter: Gang Chen | Author(s): Chunwei Xu, W. Wang, Wu Zhuang, Z. Huang, Z. Song, Y. Chen, W. Liu, Rongrong Chen, Y. Guan, X. Yi, Meiyu Fang, T.F. Lv, Yong Song
  Abstract
  
  Loading...
20152

+
P1.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 22607
  
  +
  
  P1.03-052 - Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
  
  09:30 - 09:30 | Presenter: Yayi He | Author(s): C. Zhao, X. Li, Shengxiang Ren, Tao Jiang, J. Zhang, C. Su, X. Chen, Weijing Cai, G. Gao, W. Li, Fengying Wu, J. Li, J. Zhao, Fei Zhou, Q. Hu, Fred R. Hirsch, Caicun Zhou
  Abstract
  
  Loading...
- 22608
  
  +
  
  P1.03-053 - Taiwan Real Word Efficacy of 1st Line EGFR TKIs Treatment in EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Chih-Yen Tu | Author(s): C. Chen, T. Hsia, W. Liao, W. Chen, W. Hsu
  Abstract
  
  Loading...
20154

+
P1.05 - Early Stage NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- 22623
  
  +
  
  P1.05-001 - Microwave Ablation plus Recombinant Human Endostatin (Endostar) versus Microwave Ablation Alone in Inoperable Stage I Non Small Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Guanghui Huang | Author(s): X. Ye, X. Yang, A. Zheng, W. Li, J. Wang, X. Han, Z. Wei, M. Meng, Y. Ni
  Abstract
  
  Loading...
20164

+
P1.15 - SCLC/Neuroendocrine Tumors
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- 22794
  
  +
  
  P1.15-009 - Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)
  
  09:30 - 09:30 | Presenter: Shengxiang Ren | Author(s): G. Gao, W. Li, X. Chen, Fengying Wu, C. Su, J. Zhao, Y. Sun, Weijing Cai, Caicun Zhou
  Abstract
  
  Loading...
20118

+
OA 03 - Mediastinal and Esophageal Tumor: Insight and New Treatment
- 11:00 - 12:30
- 10/16/2017
- Location: Room 311 + 312
- Type: Oral
- Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Moderators:M. Chida, Jhingook Kim
- 22950
  
  +
  
  OA 03.04 - A Phase II Study of Pembrolizumab for Patients with Refractory or Relapsed Thymic Epithelial Tumor
  
  11:30 - 11:40 | Presenter: Jinhyun Cho | Author(s): K.H. Yoo, Hansang Lee, H.K. Kim, Y. Kim, J.H. Cho, S.W. Lim, Song Ee Park, Jong-Mu Sun, S. Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
  Abstract
  
  Loading...
20124

+
MA 06 - Lung Cancer Biology I
- 15:45 - 17:30
- 10/16/2017
- Location: Room 501
- Type: Mini Oral
- Track: Biology/Pathology
- Moderators:N. Motoi, Keith M Kerr
- 23873
  
  +
  
  MA 06.09 - Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC
  
  16:35 - 16:40 | Presenter: Xu-Chao Zhang | Author(s): Z. Liang, Y. Chen, H. Zhang, G. Wu, Y. Lu, Z. Liang, Ying Cheng, Y. Hu, J. Wang, J. Ying, W. Liu, Y. Wu
  Abstract
  
  Loading...
20167

+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 23274
  
  +
  
  P2.03-003 - Cost Effectiveness of Gefitinib for Lung Adenocarcinoma Patients with Mutant Epidermal Growth Factor Receptor
  
  09:30 - 09:30 | Presenter: Chun-Ru Chien | Author(s): T. Hsia, Chih-Yen Tu, H. Chen, S. Chen, C. Chen, W. Liao, C. Li, C. Lin, C. Li
  Abstract
  
  Loading...
- 23299
  
  +
  
  P2.03-028 - Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial
  
  09:30 - 09:30 | Presenter: Yuankai Shi | Author(s): X. Hu, S. Zhang, N. Yang, Y. Zhang, W. Li, X. Han, H. Mo, Y. Sun
  Abstract
  
  Loading...
20171

+
P2.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- 23400
  
  +
  
  P2.07-025 - Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Song Ee Park | Author(s): Y. Kim, H.K. Kim, H. Lee, J.H. Cho, S.W. Lim, S. Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Jong-Mu Sun
  Abstract
  
  Loading...
- 23422
  
  +
  
  P2.07-047 - Poor Performance Status and BRAF Mutation Predict Grade 3-5 Immune-Related Adverse Events in Pts with Advanced NSCLC
  
  09:30 - 09:30 | Presenter: Yan Wang | Author(s): Jinpeng Shi, W. Li, G. Gao, Shengxiang Ren, Caicun Zhou
  Abstract
  
  Loading...

Session Information

WCLC 2017

18th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West

+

JCSE 01.25 - Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC

+

P1.01 - Advanced NSCLC

+

P1.01-034 - Cerebrospinal Fluid and Plasma Tumor DNA Profiling Reveals Heterogeneity of CNS Metastasis in Patients with Non-Small-Cell Lung Cancer

+

P1.02 - Biology/Pathology

+

P1.02-046 - Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations

+

P1.03 - Chemotherapy/Targeted Therapy

+

P1.03-052 - Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism

+

P1.03-053 - Taiwan Real Word Efficacy of 1st Line EGFR TKIs Treatment in EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

+

P1.05 - Early Stage NSCLC

+

P1.05-001 - Microwave Ablation plus Recombinant Human Endostatin (Endostar) versus Microwave Ablation Alone in Inoperable Stage I Non Small Cell Lung Cancer

+

P1.15 - SCLC/Neuroendocrine Tumors

+

P1.15-009 - Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

+

OA 03 - Mediastinal and Esophageal Tumor: Insight and New Treatment

+

OA 03.04 - A Phase II Study of Pembrolizumab for Patients with Refractory or Relapsed Thymic Epithelial Tumor

+

MA 06 - Lung Cancer Biology I

+

MA 06.09 - Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC

+

P2.03 - Chemotherapy/Targeted Therapy

+

P2.03-003 - Cost Effectiveness of Gefitinib for Lung Adenocarcinoma Patients with Mutant Epidermal Growth Factor Receptor

+

P2.03-028 - Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial

+

P2.07 - Immunology and Immunotherapy

+

P2.07-025 - Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer

+

P2.07-047 - Poor Performance Status and BRAF Mutation Predict Grade 3-5 Immune-Related Adverse Events in Pts with Advanced NSCLC

Stay Connected